Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5132MR)

This product GTTS-WQ5132MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_001167928.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3556
UniProt ID	Q9NPH3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5132MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4745MR	IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	BPS-804
GTTS-WQ12191MR	IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MORAb-022
GTTS-WQ2283MR	IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ALXN1007
GTTS-WQ11366MR	IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	MEDI-573
GTTS-WQ12114MR	IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MORAb-003
GTTS-WQ12478MR	IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	NN-8226
GTTS-WQ14078MR	IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	REGN-421
GTTS-WQ4200MR	IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	BIIB019

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST